Go Pro
→ Rickards Predicts: Trump to buy tiny $2 stock? (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$4.89
+1.0%		$4.73
$3.99
▼
$10.99
$401.22M1.5929,583 shs296,441 shs
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$13.14
-1.7%		$12.11
$9.40
▼
$31.55
$225.35M1.74462,125 shs252,185 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
+1.26%-3.01%+9.75%+10.76%-1.63%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-0.07%-1.40%+19.27%+20.78%-51.73%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$4.89
+1.0%		$4.73
$3.99
▼
$10.99
$401.22M1.5929,583 shs296,441 shs
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$13.14
-1.7%		$12.11
$9.40
▼
$31.55
$225.35M1.74462,125 shs252,185 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
+1.26%-3.01%+9.75%+10.76%-1.63%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-0.07%-1.40%+19.27%+20.78%-51.73%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
3.00
Buy$18.75283.44% Upside
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
3.00
Buy$24.5086.45% Upside

Current Analyst Ratings Breakdown

Latest TNXP and LXEO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/10/2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy$27.00
7/30/2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/28/2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/28/2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/13/2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/10/2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/25/2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/25/2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$12.00 ➝ $9.00
6/24/2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageStrong-Buy$26.00
6/24/2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
N/AN/AN/AN/A$2.87 per shareN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$13.11M17.19N/AN/A$12.96 per share1.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$99.96M-$1.15N/AN/AN/AN/A-41.85%-38.03%N/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$124.02M-$12.94N/AN/AN/A-548.64%-68.99%-61.31%11/9/2026 (Estimated)

Latest TNXP and LXEO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$0.2852-$0.30-$0.0148-$0.30N/AN/A
8/10/2026Q2 2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$2.64-$2.44+$0.20-$2.44$7.72 million$13.54 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
N/AN/AN/AN/AN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
N/A
13.89
13.89
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/A
6.61
6.46

Institutional Ownership

CompanyInstitutional Ownership
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
60.67%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
82.26%

Insider Ownership

CompanyInsider Ownership
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
2.00%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
2.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
5882.05 million80.41 millionNot Optionable
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
5017.15 million16.81 millionNot Optionable

Recent News About These Companies

TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26
September 2 at 6:19 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tnxp-11-0-million-tonmya-133800624.html
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
September 2 at 8:14 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tonix-pharmaceuticals-participate-cantor-2026-110000379.html
Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference
September 2 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3354977/28908/en/tonix-pharmaceuticals-to-participate-in-cantor-s-2026-global-healthcare-conference.html
Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Acquires 2,000 Shares
September 1 at 4:51 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-tnxp-insider-buying-and-selling-2026-09-01/
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-tonix-pharmaceuticals-nasdaq-tnxp-ceo-buys-2758000-in-stock-2026-08-31/
Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street Zen
August 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30989230
Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-tonix-pharmaceuticals-nasdaq-tnxp-rating-increased-to-hold-at-wall-street-zen-2026-08-29/
Tonix Pharmaceuticals (NASDAQ:TNXP) Director Richard Bagger Acquires 1,000 Shares
August 25, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-tnxp-insider-buying-and-selling-2026-08-25/
Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) Director Purchases $12,600.00 in Stock
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-buying-tonix-pharmaceuticals-nasdaqtnxp-director-purchases-1260000-in-stock-2026-08-24/
Tonix Pharma Names CEO Seth Lederman Interim CMO
August 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tonix-pharma-names-ceo-seth-lederman-interim-cmo?utm_source=marketbeat.com&utm_medium=referral
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tonix-pharmaceuticals-highlights-tonmya-sales-surge-lyme-and-depression-pipeline-2026-08-18/
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript
August 17, 2026  |  fool.comhttps://www.fool.com/earnings/call-transcripts/2026/08/17/tonix-pharmaceuticals-tnxp-q2-2026-earnings-call-transcript/
Tonix Pharmaceuticals Earnings Call Highlights Surging TONMYA Momentum
August 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TNXP-Q/pressreleases/3792887/tonix-pharmaceuticals-earnings-call-highlights-surging-tonmya-momentum/
Tonix Pharmaceuticals: Stronger-Than-Expected Tonmya Launch, Expanded Market Access, and Advancing Pipeline Underpin Buy Rating
August 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/tonix-pharmaceuticals-stronger-than-expected-tonmya-launch-expanded-market-access-and-advancing-pipeline-underpin-buy-rating-ratings-news?utm_source=marketbeat.com&utm_medium=referral
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/tonix-pharmaceuticals-reports-second-quarter-2026-financial-results-and-operational-highlights-1036435291
Tonix outlines TNX-4800 Phase II with ~3,300 participants while scaling TONMYA to ~150 reps by September
August 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4630086-tonix-outlines-tnxminus-4800-phase-ii-with-3300-participants-while-scaling-tonmya-to-150-reps
Tonix Pharmaceuticals Holding C (TNXP) Q2 FY2026 earnings call transcript
August 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/TNXP/earnings/TNXP-Q2-2026-earnings_call-666911.html
Penny Stocks: What Does Tonix Pharmaceuticals (NASDAQ:TNXP) Update Signal?
August 10, 2026  |  kalkinemedia.comK
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ...
August 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tonix-pharmaceuticals-holding-corp-tnxp-210141573.html
Tonix Pharmaceuticals Q2 Earnings Call Highlights
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tonix-pharmaceuticals-q2-earnings-call-highlights-2026-08-10/
Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Earnings Results
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tonix-pharmaceuticals-nasdaqtnxp-announces-earnings-results-2026-08-10/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lexeo Therapeutics stock logo

Lexeo Therapeutics NASDAQ:LXEO

$4.89 +0.05 (+1.03%)
As of 04:00 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Tonix Pharmaceuticals stock logo

Tonix Pharmaceuticals NASDAQ:TNXP

$13.14 -0.23 (-1.72%)
As of 04:00 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas